Helixmith Obtains U.S. Patent for CAR-T Cell Therapy Technology

[Asia Economy Reporter Jang Hyowon] Helixmith announced on the 15th that it has obtained a U.S. patent for CAR-T cell therapy technology targeting TAG-72. The patent has been registered in Japan, Europe, and the United States, and is currently awaiting registration in South Korea as well as in China, Hong Kong, Australia, and Canada.

This patent pertains to cells expressing anti-sialyl Tn chimeric antigen receptors (ANTI-SIALYL TN CHIMERIC ANTIGEN RECEPTORS) and their compositions. It is a CAR-T (chimeric antigen receptor-T) cell therapy that can recognize and exert cytotoxic effects on cancers expressing the sialyl Tn (STn) antigen on the TAG-72 (Tumor Associated Glycoprotein 72) glycoprotein, which is highly expressed in solid tumors.

Helixmith has developed anti-STn CAR-T cells that can specifically recognize the STn antigen and confirmed their antitumor effects against cancer cells expressing the STn antigen on the TAG-72 glycoprotein.

Cancers that can be treated with anti-STn CAR-T cells include all cancers that overexpress TAG-72. This includes various intractable solid tumors such as colorectal cancer, ovarian cancer, gastric cancer, breast cancer, esophageal cancer, bladder cancer, lung cancer, and pancreatic cancer, and it is expected to be applied as a cancer treatment for these difficult-to-treat cancers.

Yoo Seungshin, CEO of Helixmith, said, “CAR-T cell therapy is called a miracle anticancer drug and a fourth-generation anticancer drug, and it is the most globally recognized gene therapy.” He added, “With related patents registered in the U.S., Europe, and Japan, Helixmith’s CAR-T therapy platform technology is gaining global recognition.” He further stated, “We expect that an anticancer gene cell therapy for intractable cancers overexpressing TAG-72 can be developed.”

This content was produced with the assistance of AI translation services.